Efficacy of Disitamab Vedotin in a heavily pre-treated HER2 positive lung adenocarcinoma patient: case report and literature review

Cancer therapies targeting human epidermal growth factor receptor 2 (HER2) have been attracting increasing attention worldwide, especially in lung adenocarcinoma. Disitamab vedotin is an antibody-drug conjugate designed for targeting HER2 that has been approved for urothelial carcinoma and gastric c...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Xiangjun, Guo, Jiayun, Zhou, Xiaoqi, Sun, Lingling, Lin, Jietao, Huang, Zijing, Chen, Hanrui, Lin, Lizhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519492/
https://www.ncbi.nlm.nih.gov/pubmed/36185140
http://dx.doi.org/10.1016/j.heliyon.2022.e10581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519492/
https://www.ncbi.nlm.nih.gov/pubmed/36185140
http://dx.doi.org/10.1016/j.heliyon.2022.e10581

Ejemplares similares